Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18651791 | METHOD FOR ASSESSMENT OF HEPATIC FUNCTION AND PORTAL BLOOD FLOW | May 2024 | July 2025 | Allow | 15 | 0 | 0 | No | No |
| 18632967 | CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTURE | April 2024 | September 2025 | Abandon | 17 | 0 | 1 | No | No |
| 18628751 | OLIVE DERIVED CELL CULTURE AND METHODS FOR PREPARING AND USING THE SAME | April 2024 | August 2025 | Allow | 16 | 1 | 0 | No | No |
| 18426809 | COMPOSITIONS, DEVICES AND METHODS FOR THE CONTROL IN VITRO OF CHEMICAL MICROAMBIENT IN CELL CULTURES | January 2024 | February 2026 | Abandon | 25 | 2 | 0 | No | No |
| 18427221 | BACTERIOPHAGE THERAPY | January 2024 | July 2025 | Allow | 18 | 1 | 0 | No | No |
| 18541671 | SYSTEMS FOR PRODUCTION OF PRODUCTS TO PROMOTE NITROGEN USE EFFICIENCY IN PLANTS | December 2023 | March 2025 | Allow | 15 | 1 | 1 | Yes | No |
| 18512129 | LYOPHILIZED POLYMER SCAFFOLD COMPOSITIONS, PROCESSES FOR PREPARATION AND USE IN ANABOLIC WOUND REPAIR | November 2023 | April 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18388300 | DEVICES FOR SIMULATING A FUNCTION OF A TISSUE AND METHODS OF USE AND MANUFACTURING THEREOF | November 2023 | April 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18386699 | METHOD FOR PREPARING BONE GRAFT COMPOSITION AND BONE GRAFT COMPOSITION | November 2023 | September 2025 | Abandon | 23 | 2 | 0 | No | No |
| 18372842 | MICROTOME SECTIONABLE GEL SUPPORT STRUCTURE AND METHODS | September 2023 | December 2024 | Allow | 14 | 1 | 0 | No | No |
| 18349695 | METHODS AND DEVICES FOR CELLULAR TRANSPLANTATION | July 2023 | August 2025 | Abandon | 25 | 2 | 0 | No | No |
| 18345891 | B-CELL CULTIVATION METHOD | June 2023 | February 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18177364 | PDX1 PANCREATIC ENDODERM CELLS IN CELL DELIVERY DEVICES AND METHODS THEREOF | March 2023 | July 2024 | Allow | 16 | 1 | 0 | No | No |
| 18116472 | CELL SHEET CONSTRUCT FOR NEUROVASCULAR RECONSTRUCTION AND MANUFACTURE THEREOF | March 2023 | May 2024 | Allow | 14 | 1 | 0 | Yes | No |
| 18092429 | COMPOSITIONS AND METHODS FOR DISRUPTING BIOFILM FORMATION AND MAINTENANCE | January 2023 | October 2024 | Abandon | 21 | 1 | 1 | No | No |
| 18145615 | PANCREATIC STEM CELLS AND USES THEREOF | December 2022 | July 2024 | Abandon | 19 | 0 | 1 | No | No |
| 18069299 | SPECIFICATION OF FUNCTIONAL CRANIAL PLACODE DERIVATIVES FROM HUMAN PLURIPOTENT STEM CELLS | December 2022 | January 2026 | Allow | 36 | 2 | 1 | No | No |
| 18065451 | ADMINISTRATION OF KYNURENINE DEPLETING ENZYMES FOR TUMOR THERAPY | December 2022 | March 2026 | Allow | 39 | 2 | 0 | Yes | No |
| 17981671 | MICROBIAL HOST CELLS FOR PRODUCTION OF STEVIOL GLYCOSIDES | November 2022 | May 2025 | Abandon | 30 | 2 | 1 | Yes | No |
| 17959242 | METHODS TO ENHANCE DELIVERY AND ENGRAFTMENT OF STEM CELLS INCLUDING THE IDENTIFICATION OF SPECIFIC PROSTAGANDIN E2 RECEPTORS | October 2022 | August 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17911056 | MESENCHYMAL STROMAL CELLS AND EXTRACELLULAR VESICLES FOR TREATING VIRAL INFECTIONS, INFLAMMATION, AND TISSUE FIBROSIS | September 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17941352 | METHODS TO DIFFERENTIATE STEM CELLS INTO HORMONE-PRODUCING CELLS | September 2022 | October 2025 | Allow | 37 | 1 | 2 | No | No |
| 17929890 | CARDIAC FIBROBLAST DERIVED EXTRACELLULAR MATRIX | September 2022 | May 2025 | Allow | 33 | 1 | 0 | No | No |
| 17895697 | CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTURE | August 2022 | May 2024 | Abandon | 21 | 0 | 1 | No | No |
| 17889776 | Polymeric Carriers and Methods | August 2022 | February 2024 | Allow | 18 | 0 | 1 | Yes | No |
| 17890059 | SYSTEM AND METHOD FOR MAINTAINING ORGAN VIABILITY | August 2022 | October 2025 | Allow | 38 | 1 | 1 | Yes | No |
| 17819220 | MESENCHYMAL STEM CELLS-HYDROGEL-BIODEGRADABLE OR MESENCHYMAL STEM CELLS-HYDROGEL-NONDEGRADABLE SUPPORT COMPOSITION FOR ALLEVIATING OR IMPROVING EPIDERMOLYSIS BULLOSA | August 2022 | May 2025 | Allow | 34 | 3 | 1 | No | No |
| 17798206 | COATING AGENT FOR INDUCING DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO BRAIN MICROVASCULAR ENDOTHELIUM-LIKE CELLS AND USE THEREOF | August 2022 | December 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17759954 | P450 BM3 MONOOXYGENASE VARIANTS FOR C19-HYDROXYLATION OF STEROIDS | August 2022 | November 2025 | Abandon | 39 | 1 | 1 | No | No |
| 17872467 | OVARIAN-DERIVED HYDROGELS FOR BIOMEDICAL AND BIOTECHNOLOGY APPLICATIONS | July 2022 | April 2024 | Allow | 20 | 2 | 1 | No | No |
| 17814044 | CULTURE AND DIFFERENTIATION OF PLURIPOTENT STEM CELLS | July 2022 | December 2025 | Abandon | 41 | 2 | 1 | No | No |
| 17860747 | DENTAL PRETREATMENT MATERIAL AND DENTAL TISSUE REGENERATION KIT | July 2022 | May 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17809750 | MICROORGANISMS AND METHODS FOR THE PRODUCTION OF FATTY ACIDS AND FATTY ACID DERIVED PRODUCTS | June 2022 | August 2024 | Allow | 25 | 1 | 1 | No | No |
| 17848998 | ANTI-NET COMPOUNDS FOR TREATING AND PREVENTING FIBROSIS AND FOR FACILITATING WOUND HEALING | June 2022 | May 2025 | Abandon | 35 | 2 | 1 | No | No |
| 17838127 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | June 2022 | February 2026 | Allow | 44 | 1 | 1 | Yes | No |
| 17836922 | BIOREACTOR PARADIGM FOR THE PRODUCTION OF SECONDARY EXTRA-PARTICLE HYPHAL MATRICES | June 2022 | June 2025 | Abandon | 37 | 2 | 1 | No | No |
| 17783431 | CRYOPRESERVED INSECTS AND METHODS FOR PRODUCING SAME | June 2022 | October 2025 | Allow | 40 | 1 | 1 | No | No |
| 17827128 | METHODS OF IMPLANTING ENGINEERED TISSUE CONSTRUCTS | May 2022 | May 2024 | Abandon | 24 | 3 | 1 | No | No |
| 17732190 | RECOMBINANT erIL-15 NK CELLS | April 2022 | April 2025 | Allow | 36 | 0 | 0 | No | No |
| 17437400 | STAT3 TRANSCRIPTOME FOR DESIGNING MORE POTENT NK CELLS | April 2022 | October 2025 | Abandon | 49 | 0 | 1 | No | No |
| 17771459 | SCAFFOLD FOR CELL CULTURE AND MANUFACTURING METHOD THEREOF | April 2022 | August 2025 | Allow | 39 | 1 | 1 | No | No |
| 17727293 | IN SITU EXPANSION OF ENGINEERED DEVICES FOR REGENERATION | April 2022 | April 2024 | Abandon | 24 | 1 | 0 | No | No |
| 17726498 | LIQUID-BASED CELL PRESERVATION SOLUTION AND METHOD FOR PREPARING SAME | April 2022 | October 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17766745 | COMPOSITION, FOR PREVENTION OR TREATMENT OF CANCER DISEASE, COMPRISING CYTOTOXIC T CELLS ACTIVATED BY T HELPER CELL-DERIVED EXTRACELLULAR VESICLES AS ACTIVE INGREDIENT | April 2022 | September 2025 | Allow | 42 | 1 | 1 | No | No |
| 17639618 | FUSION PROTEINS AND USES THEREOF | March 2022 | December 2025 | Allow | 46 | 2 | 1 | No | No |
| 17639170 | UROTHELIAL CELL INDUCTION AGENT AND METHOD FOR INDUCING UROTHELIAL CELLS | February 2022 | October 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17673455 | METHANOTHERMOBACTER THERMAUTOTROPHICUS STRAIN AND VARIANTS THEREOF | February 2022 | March 2025 | Allow | 37 | 2 | 1 | No | No |
| 17633414 | T CELLS HAVING ENHANCED ANTI-TUMOR ACTIVITY | February 2022 | October 2025 | Allow | 44 | 1 | 1 | No | No |
| 17580919 | METHODS OF TUMOR VACCINATION | January 2022 | April 2025 | Allow | 39 | 1 | 1 | No | No |
| 17578802 | METHOD FOR RECOVERING MICROBIAL CELLS | January 2022 | November 2024 | Abandon | 34 | 0 | 1 | No | No |
| 17596889 | TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED NEUROINFLAMMATION USING FIBROBLASTS AND DERIVATIVES THEREOF | December 2021 | June 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17550830 | Manufacturing Process for Polysaccharide Beads | December 2021 | May 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17547444 | CD34+CD41DIM MEGAKARYOCYTES PROGENITORS AND USES THEREOF FOR PRODUCING PROPLATELET-BEARING MKS AND/OR PLATELETS | December 2021 | June 2025 | Abandon | 43 | 2 | 1 | No | No |
| 17540619 | DEVICES FOR SIMULATING A FUNCTION OF A TISSUE AND METHODS OF USE AND MANUFACTURING THEREOF | December 2021 | September 2022 | Allow | 9 | 8 | 0 | No | No |
| 17536807 | SOX9-INDUCED OLIGODENDROCYTE PROGENITOR CELLS | November 2021 | August 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17614225 | AN ENGINEERED VALVE AND METHOD OF MAKING | November 2021 | July 2025 | Allow | 43 | 1 | 1 | No | No |
| 17613137 | METHODS OF CULTURING HUMAN PLURIPOTENT CELLS | November 2021 | July 2025 | Allow | 44 | 1 | 1 | No | No |
| 17595494 | SHAPED ORGANOID COMPOSITIONS AND METHODS OF MAKING SAME | November 2021 | September 2025 | Allow | 46 | 1 | 1 | No | No |
| 17611669 | Transplantable cell composition comprising eukaryotic cells in a nanofibrillar cellulose hydrogel, method for preparing thereof and use of nanofibrillar cellulose | November 2021 | September 2025 | Abandon | 46 | 0 | 2 | No | No |
| 17608052 | METHODS OF TREATING DIABETES USING DEVICES FOR CELLULAR TRANSPLANTATION | November 2021 | June 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17594752 | FIBROBLAST CELL THERAPY FOR TREATMENT OF OSTEOPOROSIS | October 2021 | October 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17606217 | WISKOTT-ALDRICH SYNDROME GENE HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE | October 2021 | April 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17504788 | METHODS FOR MONITORING TREATMENT OF CHRONIC LIVER DISEASE | October 2021 | January 2025 | Allow | 39 | 3 | 1 | No | No |
| 17602917 | METHOD FOR PREPARATION OF CANCER/TESTIS ANTIGEN-SPECIFIC T-CELLS | October 2021 | October 2025 | Abandon | 48 | 2 | 0 | No | No |
| 17494322 | Modified Extracellular Enveloped Virus | October 2021 | June 2025 | Allow | 45 | 1 | 1 | No | No |
| 17482674 | Methods for Regenerating Defective or Absent Myocardium | September 2021 | December 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17437485 | MICROGLIAL PROGENITORS FOR REGENERATION OF FUNCTIONAL MICROGLIA IN THE CENTRAL NERVOUS SYSTEM AND THERAPEUTICS USES THEREOF | September 2021 | April 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17467834 | VITRO CULTURE MODEL OF ANISOTROPIC TO ISOTROPIC TRANSITIONS | September 2021 | April 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17434559 | BACILLUS SUBTILIS NATTO AND METHOD FOR PRODUCING MK-7 | August 2021 | August 2025 | Allow | 47 | 1 | 1 | No | No |
| 17432474 | RECOMBINANT ANTIMICROBIAL MULTIDOMAIN POLYPEPTIDE, METHODS OF PRODUCING AND USES THEREOF | August 2021 | January 2026 | Allow | 52 | 2 | 0 | No | No |
| 17404276 | METHODS AND DEVICES FOR HARVESTING AND PROCESSING CONNECTIVE TISSUE PRECURSOR CELLS FROM AUTOLOGOUS FAT | August 2021 | February 2024 | Allow | 30 | 1 | 0 | Yes | No |
| 17394125 | DELIVERY OF BIOMOLECULES TO IMMUNE CELLS | August 2021 | May 2025 | Allow | 45 | 4 | 0 | No | No |
| 17390956 | PROCESS FOR SIMULTANEOUS PRODUCTION OF CITRIC ACID AND CELLULOLYTIC ENZYMES | July 2021 | November 2024 | Allow | 39 | 1 | 0 | No | No |
| 17376341 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | July 2021 | March 2023 | Allow | 20 | 2 | 1 | No | No |
| 17372325 | HIGH POTENCY STABLE FORMULATIONS OF VAGINAL LACTOBACILLUS | July 2021 | January 2025 | Allow | 42 | 3 | 1 | Yes | No |
| 17353337 | BACTERIOPHAGE THERAPY | June 2021 | October 2023 | Allow | 28 | 1 | 0 | No | No |
| 17415456 | CELL CULTURE SUBSTRATE | June 2021 | September 2024 | Allow | 39 | 1 | 0 | Yes | No |
| 17415504 | CELL CULTURE SUBSTRATE | June 2021 | May 2025 | Allow | 47 | 3 | 0 | No | No |
| 17343949 | GENERATION OF GLUCOSE-RESPONSIVE BETA CELLS | June 2021 | September 2024 | Abandon | 39 | 2 | 1 | No | No |
| 17332718 | RECOMBINANT FLAVIN-ADENINE DINUCLEOTIDE GLUCOSE DEHYDROGENASE AND USES THEREOF | May 2021 | March 2025 | Allow | 45 | 1 | 0 | No | No |
| 17303133 | METHODS OF ENHANCING FIBROBLAST THERAPEUTIC ACTIVITY | May 2021 | June 2025 | Allow | 49 | 4 | 0 | No | No |
| 17318056 | CELL CULTURE | May 2021 | January 2024 | Allow | 32 | 1 | 1 | No | No |
| 17286372 | PROCESS FOR PRODUCING AMMONIUM (METH-) ACRYLATE | April 2021 | June 2024 | Allow | 38 | 1 | 1 | Yes | No |
| 17285948 | MICROBIAL CELL WITH IMPROVED IN VIVO CONVERSION OF THEBAINE/ORIPAVINE | April 2021 | August 2025 | Allow | 52 | 2 | 1 | No | No |
| 17227252 | HUMAN UTERINE CERVICAL STEM CELL POPULATION AND USES THEREOF | April 2021 | October 2024 | Allow | 42 | 2 | 1 | No | No |
| 17283562 | FUMONISIN DEGRADING ENZYME FUMDPS AND GENE AND USE THEREOF | April 2021 | June 2025 | Allow | 50 | 2 | 0 | No | No |
| 17213436 | IN SITU EXPANSION OF ENGINEERED DEVICES FOR REGENERATION | March 2021 | October 2021 | Allow | 7 | 1 | 1 | Yes | No |
| 17205597 | COMPOSITIONS AND METHODS FOR TREATING HEART DISEASE | March 2021 | April 2025 | Allow | 49 | 2 | 0 | No | No |
| 17186525 | INFUSED PARTICLES | February 2021 | November 2025 | Abandon | 56 | 4 | 1 | No | Yes |
| 17181953 | Compositions for Treatment or Prevention of Infectious Inflammatory Diseases, or Compositions for Immune Enhancement, Comprising, Tryptophanyl-tRNA Synthetase as an Active Ingredient | February 2021 | January 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17176569 | Method of Tissue Repair | February 2021 | January 2024 | Abandon | 35 | 1 | 0 | No | No |
| 17156178 | REPROGRAMMING OF CELLS TO A NEW FATE | January 2021 | October 2025 | Abandon | 56 | 1 | 1 | No | No |
| 17155059 | OLIVE DERIVED CELL CULTURE AND METHODS FOR PREPARING AND USING THE SAME | January 2021 | June 2024 | Abandon | 41 | 2 | 1 | No | No |
| 17148614 | AGENTS AND METHODS USING THEREOF FOR THE PREVENTION AND TREATMENT OF STEM CELL MUSCLE DISORDERS | January 2021 | January 2025 | Abandon | 48 | 2 | 1 | No | Yes |
| 17137557 | CONTROLLED AGGREGATION OF CELLS | December 2020 | July 2024 | Abandon | 42 | 2 | 0 | No | No |
| 17129058 | PROCESS FOR PRODUCING FUEL USING TWO FERMENTATIONS | December 2020 | August 2023 | Allow | 32 | 0 | 1 | No | No |
| 17128303 | METHOD FOR MAKING BIOLOGICAL MATERIAL TRANSPARENT AND USE THEREOF | December 2020 | February 2025 | Abandon | 50 | 4 | 0 | Yes | No |
| 17128654 | CLEARING REAGENT FOR BIOLOGICAL MATERIAL, AND USE THEREOF | December 2020 | February 2025 | Abandon | 50 | 4 | 0 | Yes | No |
| 17253118 | EVALUATION METHOD FOR GENOMIC ABNORMALITIES IN CELLS | December 2020 | May 2025 | Abandon | 53 | 1 | 1 | No | No |
| 17111147 | SOFT TISSUE REPAIR AND METHODS FOR PREPARING SAME | December 2020 | October 2023 | Allow | 35 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BARRON, SEAN C.
With a 38.9% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 18.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BARRON, SEAN C works in Art Unit 1653 and has examined 612 patent applications in our dataset. With an allowance rate of 52.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.
Examiner BARRON, SEAN C's allowance rate of 52.1% places them in the 14% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BARRON, SEAN C receive 2.76 office actions before reaching final disposition. This places the examiner in the 81% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by BARRON, SEAN C is 39 months. This places the examiner in the 25% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +32.5% benefit to allowance rate for applications examined by BARRON, SEAN C. This interview benefit is in the 80% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 17.5% of applications are subsequently allowed. This success rate is in the 15% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 18.8% of cases where such amendments are filed. This entry rate is in the 22% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 52.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 46% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 62.5% of appeals filed. This is in the 40% percentile among all examiners. Of these withdrawals, 63.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 83.2% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.5% of allowed cases (in the 60% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.4% of allowed cases (in the 79% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.